
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Biomotion Sciences Warrant (SLXNW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: SLXNW (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $0
1 Year Target Price $0
0 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.62% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.12 | 52 Weeks Range 0.01 - 0.18 | Updated Date 06/5/2025 |
52 Weeks Range 0.01 - 0.18 | Updated Date 06/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -193.54% | Return on Equity (TTM) -116.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 996278 |
Shares Outstanding - | Shares Floating 996278 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biomotion Sciences Warrant
Company Overview
History and Background
Biomotion Sciences is a company focused on developing and commercializing medical technology. Details on its founding year and specific milestones are unavailable without access to a specific warrant ticker symbol. As a warrant, it grants the holder the right to purchase shares of the underlying company, Biomotion Sciences, at a specified price and date. Warrants are often issued to raise capital or as part of a debt offering.
Core Business Areas
- Biomedical Engineering: Development of new medical devices and technologies for improving patient outcomes.
- Medical Device Commercialization: Bringing developed devices to market through sales, distribution, and marketing efforts.
- Research and Development: Focusing on future biomedical and medical technologies.
Leadership and Structure
Details about the specific leadership team and organizational structure of Biomotion Sciences are not available without a specific warrant ticker. Leadership typically includes a CEO, CFO, and other key executives, while the structure will depend on the company's size and business focus.
Top Products and Market Share
Key Offerings
- Medical Devices (General): Biomotion Sciences likely offers specialized medical devices. Detailed information about specific product names, market share, users, or revenue contribution and the competitors for those products is not available. Competitors vary greatly depending on the specific device.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, strict regulatory oversight, and increasing demand driven by an aging population and advancements in healthcare technology.
Positioning
Without specific product details, Biomotion Sciences' positioning is difficult to determine. It likely competes in specific niches within the broader medical device market, potentially differentiating itself through technology, innovation, or cost.
Total Addressable Market (TAM)
The global medical device market is in the hundreds of billions of dollars. Biomotion Sciences' TAM depends on its specific product focus. The companyu2019s positioning will determine its percentage of this TAM.
Upturn SWOT Analysis
Strengths
- Innovative technology
- Strong R&D capabilities
- Proprietary technology or patents
- Experienced management team
Weaknesses
- Limited financial resources (common for smaller medical device companies)
- Dependence on regulatory approvals
- Concentrated product portfolio
- Lack of established brand recognition
Opportunities
- Expanding into new geographic markets
- Developing new applications for existing technologies
- Strategic partnerships and acquisitions
- Growing demand for specific medical devices
Threats
- Intense competition
- Changing regulatory landscape
- Product liability risks
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- JNJ
- MDT
- BSX
- ABT
- SYK
Competitive Landscape
Biomotion Sciences faces competition from large, established medical device companies with significant resources and market share. Its ability to compete depends on its technology, innovation, and ability to secure regulatory approvals and commercialize its products effectively.
Growth Trajectory and Initiatives
Historical Growth: Not available.
Future Projections: Future growth prospects for Biomotion Sciences are unknown without detailed product and financial information. Growth is dependent on successful product development, regulatory approvals, and market adoption.
Recent Initiatives: Information on recent strategic initiatives is not available.
Summary
Biomotion Sciences, represented by its warrant, is a small medical device company facing significant competition. Its success hinges on the development and commercialization of innovative technologies. Regulatory hurdles and financial constraints are key challenges. A strong competitive landscape needs to be considered when accessing the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (if available)
- Industry reports
- Market research
Disclaimers:
This analysis is based on limited information and general industry knowledge. It should not be considered investment advice. The warrant's value is speculative and subject to market conditions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomotion Sciences Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-08-16 | Chairman & CEO Mr. Ilan Hadar M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://silexion.com |
Full time employees 11 | Website https://silexion.com |
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.